Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611468 · ClinicalTrials.gov registry record · Phase 1
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
A Phase 1 study, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00611468 is a Phase 1 study that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 29 participants.
The verdict
NCT00611468, a Phase 1 study, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the best dose of the combination of two approved drugs, intravenous topotecan and oral erlotinib.
Interventions
- DRUG Topotecan
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00611468
The ClinicalTrials.gov registry entry for NCT00611468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topotecan is the first listed.
NCT00611468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00611468 about?
NCT00611468 is a clinical study titled "Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors". The purpose of this research study is to determine the best dose of the combination of two approved drugs, intravenous topotecan and oral erlotinib.
What is the current status of trial NCT00611468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2006-06. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00611468?
The interventions under investigation include: Topotecan (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00611468?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.